Literature DB >> 10683087

Short-course palliative radiotherapy in non-small-cell lung cancer: results of a prospective study.

M Lupattelli1, E Maranzano, R Bellavita, F Chionne, S Darwish, F Piro, P Latini.   

Abstract

From February 1993 to October 1997, 91 consecutive patients with inoperable (stage IIIB-IV) histologically confirmed non-small-cell lung cancer underwent palliative hypofractionated radiotherapy. Recently, the Medical Research Council studies on hypofractionated short-course radiotherapy (8.5 Gy x 2) have reported high control of symptoms caused by thoracic disease without toxicity. Based on these experiences and our previous positive trial on short-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression, a prospective study of short-course palliative radiotherapy in non-small-cell lung cancer was carried out. The regimen was 16 Gy given in two 8-Gy fractions, 1 week apart. Eighty-one patients were evaluable for response to treatment. Forty-eight (59%) patients were 65 years or older. Forty (49%) patients were naive to radiotherapy, whereas 41 (51%) had previous cisplatin-based chemotherapy. All but four stage IV patients (95%) had poor Eastern Cooperative Oncology Group performance status (i.e., 2-3). Clinical palliation was achieved in 62 (77%) patients. Performance status improved in 59 (73%) patients. The median palliation time ranged from 28% to 57% of patient survival. The median survival from the beginning of treatment was 148 days (range, 5-681 days). No difference in overall survival according to stage and previous chemotherapy was observed. Only performance status conditioned survival (performance status 1-2 vs. performance status 3; p = 0.0289). Short-course radiotherapy gave good results in terms of clinical palliation for thoracic symptoms, even in patients with poor performance status and pretreated with chemotherapy. The median palliation time was approximately 50% of patient survival time. Treatment was generally well tolerated-only 4 (5%) patients experienced World Health Organization grade III dysphagia. No late toxicity was recorded. The two-fraction regimen had social and economic advantages compared with the conventional ones.

Entities:  

Mesh:

Year:  2000        PMID: 10683087     DOI: 10.1097/00000421-200002000-00024

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  9 in total

Review 1.  Lung cancer 5: state of the art radiotherapy for lung cancer.

Authors:  A Price
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.

Authors:  Rosemary Stevens; Fergus Macbeth; Elizabeth Toy; Bernadette Coles; Jason F Lester
Journal:  Cochrane Database Syst Rev       Date:  2015-01-14

Review 3.  Metastasis to nervous system: spinal epidural and intramedullary metastases.

Authors:  Melike Mut; David Schiff; Mark E Shaffrey
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

4.  Does high-dose radiotherapy benefit palliative lung cancer patients?: An intradepartmental comparison of two dose regimens.

Authors:  C Schröder; M Ivo; A Buchali
Journal:  Strahlenther Onkol       Date:  2013-05-31       Impact factor: 3.621

5.  Palliative thoracic radiotherapy dose, non-small cell lung cancer with oligometastases and prognosis.

Authors:  Federico L Ampil; Gloria Caldito
Journal:  Ann Thorac Med       Date:  2011-07       Impact factor: 2.219

6.  Analysis of patterns of palliative radiotherapy in north west India: a regional cancer center experience.

Authors:  Akhil Kapoor; Mukesh Kumar Singhal; Narender Kumar; Ashok Kalwar; Puneet Kumar Bagri; Satya Narayan; Raj Kumar Nirban; Harvindra Singh Kumar
Journal:  Indian J Palliat Care       Date:  2015 May-Aug

7.  The efficacy of external beam radiotherapy for airway obstruction in lung cancer patients.

Authors:  Jeong Won Lee; Jong Hoon Lee; Hoon-Kyo Kim; Byoung Yong Shim; Ho Jung An; Sung Hwan Kim
Journal:  Cancer Res Treat       Date:  2014-09-12       Impact factor: 4.679

Review 8.  A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.

Authors:  Yue Zhou; Fan Yu; Yang Zhao; Ya Zeng; Xi Yang; Li Chu; Xiao Chu; Yida Li; Liqing Zou; Tiantian Guo; Zhengfei Zhu; Jianjiao Ni
Journal:  Transl Lung Cancer Res       Date:  2020-12

Review 9.  International consensus on radiotherapy in metastatic non-small cell lung cancer.

Authors:  Zhengfei Zhu; Jianjiao Ni; Xuwei Cai; Shengfa Su; Hongqing Zhuang; Zhenzhou Yang; Ming Chen; Shenglin Ma; Conghua Xie; Yaping Xu; Jiancheng Li; Hong Ge; Anwen Liu; Lujun Zhao; Chuangzhou Rao; Congying Xie; Nan Bi; Zhouguang Hui; Guangying Zhu; Zhiyong Yuan; Jun Wang; Lina Zhao; Wei Zhou; Chai Hong Rim; Arturo Navarro-Martin; Ben G L Vanneste; Dirk De Ruysscher; J Isabelle Choi; Jacek Jassem; Joe Y Chang; Lucyna Kepka; Lukas Käsmann; Michael T Milano; Paul Van Houtte; Rafal Suwinski; Alberto Traverso; Hiroshi Doi; Yang-Gun Suh; Georges Noël; Natsuo Tomita; Roman O Kowalchuk; Terence T Sio; Baosheng Li; Bing Lu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2022-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.